

Aplastic Anemia Market Anticipated to Witness Rapid Growth from 2024 to 2034 | Insights by DelveInsight

What impact are companies like Pfizer, Regeneron Pharmaceuticals, Gamida Cell, and Elixirgen having on the evolution of the Aplastic Anemia market?

LAS VEGAS , NV, UNITED STATES, December 4, 2024 /EINPresswire.com/ -- DelveInsight's "Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of Aplastic Anemia, historical and forecasted epidemiology, and Aplastic Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To explore in-depth insights into the Aplastic Anemia market trends, treatment landscape, drug uptake, and epidemiology, click here: [Aplastic Anemia Market Forecast Report](#)

Key facts of the Aplastic Anemia Market Report:

The total Aplastic Anemia Market Size in the 7MM was approximately USD 270 million in 2023, with expected growth through the forecast period (2024–2034).

The total incident population of Aplastic Anemia in the 7MM was around 2,500 cases in 2023, with a projected increase during the forecast period.

Japan had the highest number of incident cases of Aplastic Anemia in 2023, accounting for approximately 800 cases.

Aplastic Anemia predominantly occurs in the age group of 60 years and above, accounting for approximately 70% of all cases.

Among the EU4 countries, Germany had the highest number of Aplastic Anemia cases, followed by France, with Spain reporting the lowest number in 2023.

In the United States, severe Aplastic Anemia was more common, with around 400 cases in 2023.

Key Aplastic Anemia therapies include PF-06462700, REGN7257, BL-8040, and others.

Leading companies in the Aplastic Anemia market include Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and many others.

In November 2023, the US FDA approved ALVAIZ (eltrombopag choline) for the treatment of certain forms of thrombocytopenia and severe Aplastic Anemia.

In September 2023, Kyowa Kirin received approval from the Japanese Ministry of Health, Labour, and Welfare for ROMIPLATE (AMG531/romiplostim) to expand its indication for Aplastic Anemia in Japan.

The Aplastic Anemia market is expected to grow steadily, driven by increasing awareness, the approval of new therapies, and advancements in treatment options.

Aplastic Anemia Overview

Aplastic anemia is a rare, severe non-malignant disease characterized by autoimmune destruction of early hematopoietic cells. Its global incidence ranges from 0.7 to 7.4 cases per million people annually, with higher rates in Asia than in Europe and the U.S. The condition can be congenital (e.g., Fanconi Anemia, Shwachman–Diamond Syndrome) or acquired, with most acquired cases occurring due to the immune system mistakenly attacking the bone marrow. Symptoms can vary widely, with some individuals experiencing mild, stable symptoms, while others face severe, potentially life-threatening complications.

Aplastic Anemia Epidemiology

The Aplastic Anemia epidemiology chapter in the report offers both historical and forecasted data on the disease, segmented by incident cases, severity-specific cases, and age-specific cases. It covers key regions including the United States, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan, with projections spanning from 2020 to 2034.

Aplastic Anemia Epidemiology Segmentation

The Aplastic Anemia market report provides an epidemiological analysis for the period 2020–2034 across the 7MM, segmented by:

Incident Cases

Severity-specific Cases

Age-specific Cases

Aplastic Anemia Pipeline Development Activities

The Aplastic Anemia Drugs Market Report offers a comprehensive analysis of marketed therapies and late-stage pipeline treatments (Phase II and III) for Aplastic Anemia. The drug section provides detailed insights into clinical trials, covering key aspects such as pharmacological mechanisms, designations, approval status, patent information, and a thorough evaluation of each drug's benefits and limitations.

Additionally, the report includes the latest news updates and press releases on Aplastic Anemia treatments, ensuring you stay informed on the most recent developments in the field.

Aplastic Anemia Therapies and Key Companies

REGN7257: Regeneron Pharmaceuticals

OMISIRGE (omidubicel): Gamida Cell

Explore the therapies poised to dominate the Aplastic Anemia market @ [Aplastic Anemia Treatment Landscape](#).

Scope of the Aplastic Anemia Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Aplastic Anemia Companies: Pfizer, BioLineRx Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and others.

Key Aplastic Anemia Therapies: PF-06462700, REGN7257, BL-8040, and others.

Aplastic Anemia Therapeutic Assessment: Aplastic Anemia current marketed and Aplastic Anemia emerging therapies

Aplastic Anemia Market Dynamics: Aplastic Anemia market drivers and Aplastic Anemia market barriers.

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Aplastic Anemia Unmet Needs, KOL's views, Analyst's views, Aplastic Anemia Market Access and Reimbursement

Table of Contents

1. Aplastic Anemia Market Report Introduction
2. Executive Summary for Aplastic Anemia
3. SWOT analysis of Aplastic Anemia
4. Aplastic Anemia Patient Share (%) Overview at a Glance
5. Aplastic Anemia Market Overview at a Glance
6. Aplastic Anemia Disease Background and Overview
7. Aplastic Anemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Aplastic Anemia
9. Aplastic Anemia Current Treatment and Medical Practices
10. Aplastic Anemia Unmet Needs
11. Aplastic Anemia Emerging Therapies
12. Aplastic Anemia Market Outlook
13. Country-Wise Aplastic Anemia Market Analysis (2020–2034)
14. Aplastic Anemia Market Access and Reimbursement of Therapies
15. Aplastic Anemia Market Drivers
16. Aplastic Anemia Market Barriers
17. Aplastic Anemia Appendix
18. Aplastic Anemia Report Methodology

19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Report:

[Aplastic Anemia Pipeline Report](#)

DelveInsight's "Aplastic Anemia - Pipeline Insight, 2024" report offers an in-depth analysis of the pipeline landscape, covering both clinical and non-clinical stage products. It highlights key companies in the Aplastic Anemia space, such as Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and others.

About DelveInsight

DelveInsight is a prominent consulting and market research firm in the healthcare sector. It specializes in providing comprehensive end-to-end solutions to pharmaceutical companies. Its services aim to enhance the performance of pharmaceutical businesses by offering strategic insights, data-driven analysis, and actionable recommendations.

Their expertise extends to healthcare consulting services, where they assist in market analysis, enabling companies to navigate challenges and drive business growth. By focusing on the life sciences industry, DelveInsight helps organizations make informed decisions, optimize their operations, and accelerate success in a competitive market.

Jatin Vimal

DelveInsight Business Research LLP

+1 469-945-7679

info@delveinsight.com

This press release can be viewed online at: <https://www.einpresswire.com/article/766081847>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.